Abstract

Objective: Obstructive Sleep Apnea syndrome (OSAS) is the most common condition among sleep-related respiratory disorders. The etiology is not clear. However, systemic and local inflammation in the respiratory tract of the patients has been acknowledged. Monocytes and macrophages play the critical role in the inflammation process. These cells participate in the release of the proinflammatory cytokines in inflammation sites. High-density lipoprotein (HDL) cholesterol is a molecule with an anti-inflammatory effect. Monocyte/HDL cholesterol ratio (MHR) is an inflammation marker being used recently. In our study, we aimed to compare inflammation marker levels between patients diagnosed with OSAS with subsequent polysomnography and the non–OSAS group, determine the relationship between the severity of OSAS and MHR and, investigate the utility of the MHR for diagnosing OSAS.

Materials and Methods: The data from the patients' files who had polysomnography due to OSAS symptoms in our unit between July 2017 and December 2017 have been retrospectively analyzed, and polysomnography results were recorded. Demographic data and the results of biochemistry and complete blood count panels of patients with OSAS and who were not also were recorded.

Results: Out of 147 patients who underwent polysomnography in the period identified, 104 were diagnosed with OSAS. Monocyte count and MHR values were significantly high (p<0.0001 in both) and HDL levels were significantly low (p=0.03) in OSAS group. There was also a moderately significant positive correlation between apnea–hypopnea index (AHI) and MHR (p<0.0001, r=0.411).

Conclusion: MHR may be a useful tool for diagnosing OSAS. Because of the positive correlation between MHR and AHI which represents the severity of the disease, MHR may be used for the classification of OSAS.

Keywords
Obstructive Sleep Apnea syndrome, monocyte, HDL, cholesterol, polysomnography

Received/Geliş Tarihi : 03.03.2018
Accepted/Kabul Tarihi : 01.10.2018

doi:10.4274/meandros.galenos.2018.63935
Introduction

Obstructive Sleep Apnea syndrome (OSAS) is a syndrome characterized by a repeated full or partial airflow interruption in the airways during sleep (1). Prevalence rates vary from population to population and according to the parameters used to define OSAS (2-5). In a study of patients with the complaint of diurnal sleepiness, OSAS diagnosis rates were found to be 4% in males and 2% in females aged 30-60 years (6). Previous studies have determined high rates of systemic inflammation markers in OSAS patients in addition to airway inflammation and the majority of these inflammation markers have been determined to be related to the presence of OSAS and related to the severity of OSAS (7-10). Monocytes and macrophages are the most important types of cells that induce proinflammatory cytokine expression in the inflammation region (11). High-density lipoprotein (HDL) cholesterol is known to have antioxidant and anti-inflammatory effects. The monocyte/HDL-cholesterol ratio (MHR) has recently become a widely used marker of inflammation. A correlation has been established between MHR and several diseases. There are few studies in literature that have investigated the relationship between MHR and OSAS. In our study, we aimed to compare inflammation marker levels between patients diagnosed with OSAS based on polysomnography and the control group, determine the relationship between the severity of OSAS and MHR and, investigate the utility of the MHR for diagnosing OSAS.

Materials and Methods

This is a cross-sectional case control study and the study protocol was approved by Local Ethics Committee of Karabük University Training and Research Hospital (2018-1/28). The data from the patients’ files who had polysomnography due to OSAS symptoms in our university between July 2017 and December 2017 have been retrospectively analyzed. Patients who had acute or chronic infections, renal (glomerular filtration rate <90 mL/min/1.73 m²), hepatic, autoimmune and oncological diseases were excluded from the study. The parameters such as sex, age, height, weight, smoking habits, comorbidities, the results of polysomnography (PSG) and biochemistry and complete blood count panels were recorded. The patients who had an Apnea-Hypopnea index (AHI)≥5 according to PSG were categorized as OSAS and the patients who had AHI<5 were classified as a control group. In OSAS group the severity of the disease was considered as mild with 5-15, moderate with 16-30 and severe with >30 points according to AHI (12). MHR was calculated as the division of the monocyte count by HDL level.

Statistical Analysis

Analyses of the study data were made using SPSS Statistics 22.0 software (IBM Corp., NY, USA). Mean ± standard deviation, median (25-75th percentiles) or n (%) were used for descriptive statistics. Conformity of the data to normal distribution was assessed with the Shapiro-Wilk test. The chi-square test was used for comparisons of the categorical data. Variables with normal distribution were compared with the Student’s t-test and for variables not showing normal distribution, the Mann-Whitney U test was used. The Kruskal-Wallis test was used to compare MHR between control and OSAS subgroups. Post-hoc analysis was done as pairwise comparisons. Spearman’s correlation was used for relationship between AHI and MHR. Receiver operating characteristic (ROC) curve analysis was applied to determine the cutoff value for MHR use in OSAS diagnosis. A two-tailed p value of p<0.05 was accepted as statistically significant.
Results

The data of 147 patients who had PSG between July and December 2017 was accessed. According to the AHI, the patients were separated into 2 groups as those determined with OSAS (n=104) with AHI≥5, and those without OSAS (n=43) with AHI<5. In OSAS group; 50% of patients (n=52) had mild OSAS, 20.2% (n=21) had moderate OSAS and 29.8% had (n=31) heavy OSAS. The baseline characteristics of OSAS and control groups are shown in Table 1. The absolute monocyte count was found to be statistically significantly higher in the OSAS group than in the control group (p<0.001), and the HDL-cholesterol level was statistically significantly lower (p=0.03). The other laboratory parameters were found to be similar in both groups (p>0.05) (Table 2). The MHR value of the OSAS group was found to be statistically significantly high compared to that of the control group (11.64 vs 7.83, p<0.001). The MHR values of the OSAS and control groups are shown in Figure 1. In the ROC analysis, the area under the curve was found to be 0.822 (p<0.001). The cutoff value of MHR was determined to be 10.12 in the diagnosis of OSAS with sensitivity of 67.3% and specificity of 81.4% (Figure 2).

Table 1. Baseline characteristics of the Obstructive Sleep Apnea syndrome and control groups

| Variable          | OSAS             | Control          | p    |
|-------------------|------------------|------------------|------|
| Age (years)       | 51.1±12.1        | 47.4±11.4        | 0.080|
| Female Male       | 82 (78.8%) 22 (21.2%) | 26 (60.5%) 17 (39.5%) | 0.378|
| DM (+)            | 25 (24%)         | 12 (27.9%)       | 0.678|
| HT (+)            | 43 (41.3%)       | 18 (41.9%)       | 1.000|
| CAD (+)           | 7 (6.7%)         | 4 (9.3%)         | 0.731|
| OPD (+)           | 3 (2.9%)         | 2 (4.7%)         | 0.630|
| Smoking (+)       | 38 (36.5%)       | 12 (27.9%)       | 0.345|

OSAS: Obstructive Sleep Apnea syndrome, DM: Diabetes mellitus, HT: Hypertension, CAD: Coronary arterial disease, OPD: Obstructive pulmonary disease

Table 2: Comparison of the blood panels between the Obstructive Sleep Apnea syndrome and control groups

| Variable            | OSAS             | Control          | p    |
|---------------------|------------------|------------------|------|
| Leukocyte (10^3/µL)| 7610±1870        | 6370±1530        | <0.001|
| Neutrophil (10^3/µL)| 4080±1270       | 3290±960         | <0.001|
| Lymphocyte (10^3/µL)| 2730±1790       | 2510±710         | 0.113|
| Monocyte (10^3/µL)  | 471.8 (397-607)  | 328.9 (282-392)  | <0.001|
| Hb (gr/dL)          | 14.8 (13.7-15.8) | 13.3 (12.4-15)   | 0.567|
| Thrombocyte (10^3/µL)| 249 (210-285)  | 237 (204-278)    | 0.531|
| Glucose (mg/dL)     | 87 (79-99)       | 82 (75-105)      | 0.439|
| Urea (mg/dL)        | 31 (27-37)       | 32 (27-38)       | 0.951|
| Creatinin (mg/dL)   | 0.86±0.1         | 0.77±0.2         | 0.09 |
| Total-cholesterol (mg/dL)| 193.68±40.7 | 195.33±30.7 | 0.812|
| HDL-cholesterol (mg/dL) | 39.5 (34-47)   | 42.8 (38-54)    | 0.037|
| Height (m)          | 1.70 (1.63-1.75) | 1.64 (1.58-1.70) | 0.001|
| Weight (kg)         | 90.5 (80-103)    | 90 (83-98)       | 0.422|
| BMI (kg/m^2)        | 32.4 (28.1-35.4)| 33.9 (28.3-37.7)| 0.255|

OSAS: Obstructive Sleep Apnea syndrome, Hb: Hemoglobin, HDL: High-density lipoprotein, BMI: Body mass index
There was statistically significant difference between OSAS subgroups and control group regarding MHR (p<0.001). The MHR values of the OSAS and control groups are shown in Figure 3. The evaluations of patients with OSAS showed a statistically significant, moderately strong correlation between AHI and MHR (p<0.001, r=0.411). The correlations between AHI and MHR are shown in Figure 4.

Discussion

As MHR is an inexpensive and readily available parameter, it has become more widely used in recent years, and has been related to several clinical conditions (13-16). The relationship between OSAS and MHR was first investigated by Atan et al. (17) in 2007, and it was determined that MHR could be a predictive marker in OSAS diagnosis. In the present study, the value of MHR of the patients with OSAS was determined to be statistically significantly higher than that of the control group. In this respect, the data of the current study are consistent with the results of the study by Atan et al. (17) In a recent multicentre study by Inonu Koseoglu et al. (18), the relationship of MHR and cardiovascular disease was investigated in OSAS patients and it was determined that MHR, as a systemic inflammation marker, could predict cardiovascular disease in OSAS patients. In the same study, a relationship was found between MHR and OSAS severity. The results of the current study demonstrated that as the severity of OSAS increases, MHR increases. Furthermore, a moderately strong positive correlation was determined between AHI and MHR. Our results were similar to the findings of the Inonu Koseoglu et al. (18) study. With an increase in the number of monocytes, which play an active role in inflammation, the MHR increases, and a decrease in HDL-cholesterol can also lead to an increase in MHR. In a study by Tamaki et al. (19), the monocyte count in OSAS patients was determined to be increased compared to the control group. In the current study, the monocyte count of the OSAS group was found to be statistically significantly higher than that of the control group. In a study evaluating the metabolic effects of OSAS in elderly patients, Zhuo et al. (20) showed that HDL-cholesterol was lower in the OSAS group than in the control group. In the current study, the HDL-cholesterol level was determined to be low in the OSAS group. These results of the current study were similar to those of Zhuo et al. (20) Moreover,
the MHR calculated with the absolute monocyte count and HDL-cholesterol values was found to be statistically significantly high in the OSAS group of the current study compared to the control group.

Conclusion
Along with the limitations of the smallness of the sample size and the retrospective design of the study, the rarity of studies regarding the importance of MHR in OSAS patients in the literature increases the significance of our research. MHR may be a useful tool in patients with clinically compatible with OSAS. Because positive correlation was detected between MHR and AHI suggesting that this parameter may be used for evaluations of the disease severity. More prospective and comprehensive studies are needed in order to understand whether MHR can be used in the classification of OSAS in the future.

Ethics
Ethics Committee Approval: Ethical approval for this study was obtained from the Karabük University Training and Research Hospital non-Interventional Clinical Research Ethics Committee (2018-1/28).
Informed Consent: It was not taken.
Peer-review: Externally peer-reviewed.

Authorship Contributions
Concept: M.A., O.Y., Design: M.A., O.Y., Data Collection or Processing: M.A., O.Y., Analysis or Interpretation: M.A., O.Y., Literature Search: M.A., O.Y., Writing: M.A., O.Y.

Conflict of interest: The authors declare that they have no conflict of interest.

Financial Disclosure: The authors declare that they have no financial interests.

References
1. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001; 163: 685-9.
2. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 136-43.
3. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163: 608-13.
4. Bearpark H, Elliott L, Grunstein R, Cullen S, Schneider H, Althaus W, et al. Snoring and sleep apnea. A population study in Australian men. Am J Respir Crit Care Med 1995; 151: 1459-65.
5. Ip MS, Lam B, Lauder IJ, Tsang KW, Chung KF, Mok YW, et al. A community study of sleep-disordered breathing in middle-aged Chinese men in HongKong. Chest 2001; 119: 62-9.
6. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-5.
7. Mutlu LC, Tülbäş F, Alp R, Kaplan G, Yildiz ZD, Hürel A. Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea syndrome. Eur Rev Med Pharmacol Sci 2017; 21: 4161-6.
8. Sozer V, Kutnu M, Atahan E, Cilskaner Ozturk B, Hysi E, Cabuk, et al. Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome. Clin Respir J 2017.
9. Liu Y, Liu M, Shi Y. Serum Thymosin β4 Concentrations in Obstructive Sleep Apnea Syndrome Patients. J Clin Lab Anal 2016; 30: 736-40.
10. Bozkus F, Dikmen N, Demir LS. Gamma-Glutamyl Transferase Activity as a Predictive Marker for Severity of Obstructive Sleep Apnea Syndrome and Concomitant Hypertension? Clin Respir J 2018; 12: 1964-73.
11. Ancuta P, Wang J, Gabuzda D. CD16b monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 2006; 80: 1156-64.
12. Khattak HK, Hayat F, Pamboukian SV, Hahn HS, Schwartz BP, Stein PK. Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis. Tex Heart Inst J 2018; 45: 151-61.
13. Dogan A, Oylumlu M. Increased monocyte-to-HDL cholesterol ratio is related to cardiac syndrome X. Acta Cardiol 2017; 72: 516-21.
14. Bolayır A, Gokce SF, Cigdem B, Bolayır HA, Yildiz OK, Bolayır E, et al. Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients. Neurol Neurochir Pol 2017. pii: S0028-3843(17)30104-4.
15. Kadihasanoglu M, Karabay E, Yucetas U, Erkan E, Ozbek E. Relation between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Presence and Severity of Erectile Dysfunction. Aktuelle Urol 2017.
16. Aydin E, Ates I, Fettah Arikan M, Yilmaz N, Dede F. The ratio of monocyte frequency to HDL cholesterol level as a predictor of asymptomatic organ damage in patients with primary hypertension. Hypertens Res 2017; 40: 758-764.
17. Atan D, Kundi FCS, Özkan KM, Dere H. A New Predictor for Obstructive Sleep Apnea Syndrome: Monocyte to HDL Ratio. Indian J Otolaryngol Head Neck Surg 2017; 69: 142-6.
18. Inonu Koseoglu H, Pazarli AC, Kačava, Demir O. Monocyte Count/HDL Cholesterol Ratio and Cardiovascular Disease in Patients With Obstructive Sleep Apnea Syndrome: A Multicenter Study. Clin Appl Thromb Hemost 2018; 24: 139-44.
19. Tamaki S, Yamauchi M, Fukuoka A, Makinodan K, Koyama N, Tomoda K, et al. Nocturnal hypoxic stress activates invasive ability of monocytes in patients with obstructive sleep apnoea syndrome. Respirology 2009; 14: 689-94
20. Zhuo SQ, Yang XP, Chen YC, Tian XT, Lian H, Ou Q. Effect of obstructive sleep apnea syndrome on blood lipid and blood glucose in elderly hypertensive patients. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 330-2.